Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7706)
All Articles published online
|
Publishing Process of This Article
|
Oct 21, 2021 (publication date) through May 4, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550 [PMID: 34754151 DOI: 10.3748/wjg.v27.i39.6527] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i39/6527.htm |
| Number | Citing Articles |
| 1 |
Dandan Gu, Shaoyang Huang, Kai Zhao, Xiaohong Zhang, Jinjing Zhang, Wei Xiong. Global trends in resistance studies of gemcitabine and pancreatic cancer: a bibliometric and visual analysis from 2010 to 2024. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1564561
|
| 2 |
Jinping Zhang, Shuman Zhang, Isabella Dörflein, Xiaofan Ren, Susanne Pfeffer, Nathalie Britzen-Laurent, Robert Grützmann, Xianglong Duan, Christian Pilarsky. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Cancers 2023; 15(19): 4842 doi: 10.3390/cancers15194842
|
| 3 |
Congyuan Zhu, Hao Hu, Ye Ma, Shuming Xiong, Dongming Zhu. Vav1‐dependent Rac1 activation mediates hypoxia‐induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF‐1α expression. Cell Biology International 2023; 47(11): 1835 doi: 10.1002/cbin.12074
|
| 4 |
Yanjie Cao, Dedong Yu, Yun Wu, Wei Zhu. Regional intra-arterial vs. systemic chemotherapy for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1197424
|
| 5 |
Mengxin Li, Xuanzhong Wang, Xuyang Chen, Jinghui Hong, Ye Du, Dong Song. GK921, a transglutaminase inhibitor, strengthens the antitumor effect of cisplatin on pancreatic cancer cells by inhibiting epithelial-to-mesenchymal transition. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(2): 166925 doi: 10.1016/j.bbadis.2023.166925
|
| 6 |
Frederik J. Hansen, Anke Mittelstädt, Finn-Niklas Clausen, Samuel Knoedler, Leonard Knoedler, Sebastian Klöckner, Isabelle Kuchenreuther, Johanne Mazurie, Lisa-Sophie Arnold, Anna Anthuber, Anne Jacobsen, Susanne Merkel, Nadine Weisel, Bettina Klösch, Alara Karabiber, Irem Tacyildiz, Franziska Czubayko, Helena Reitberger, Amr El Gendy, Maximilian Brunner, Christian Krautz, Kerstin Wolff, Sidonia Mihai, Clemens Neufert, Jürgen Siebler, Robert Grützmann, Georg F. Weber, Paul David. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma patients. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-70916-3
|
| 7 |
Hajime Nakamura, Megumi Watanabe, Kohichi Takada, Tatsuya Sato, Fumihito Hikage, Araya Umetsu, Joji Muramatsu, Masato Furuhashi, Hiroshi Ohguro. Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel. Biomedicines 2024; 12(5): 1011 doi: 10.3390/biomedicines12051011
|
| 8 |
Shilong Han, Chuanwu Cao, Rui Liu, YiFeng Yuan, Long Pan, Minjie Xu, Chao Hu, Xiaojun Zhang, Maoquan Li, Xiaoping Zhang. GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer. Cellular Oncology 2022; 45(3): 429 doi: 10.1007/s13402-022-00675-8
|
| 9 |
Xinxing Wang, Wei Su, Chuan Qin, Ruxin Gao, Shuai Shao, Xianwen Xu, Zhenhai Zhang, Junlin Gao. Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance. Frontiers in Bioscience-Landmark 2024; 29(7) doi: 10.31083/j.fbl2907269
|
| 10 |
Erika Stefàno, Gianluca Rovito, Luca G. Cossa, Federica De Castro, Viviana Vergaro, Asjad Ali, Giulia My, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi, Massimiliano F. Peana. Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells. Bioinorganic Chemistry and Applications 2024; 2024(1) doi: 10.1155/bca/5588491
|
| 11 |
Hai Yang, Bin Liu, Dongxue Liu, Zhirong Yang, Shuman Zhang, Pengyan Xu, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Nathalie Britzen-Laurent, Robert Grützmann, Christian Pilarsky. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers 2022; 14(13): 3152 doi: 10.3390/cancers14133152
|
| 12 |
Thierry Voisin, Pascal Nicole, Valérie Gratio, Anaïs Chassac, Dounia Mansour, Vinciane Rebours, Anne Couvelard, Alain Couvineau. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.904327
|
| 13 |
Alessandro Gregori, Cecilia Bergonzini, Mjriam Capula, Rick Rodrigues de Mercado, Erik H. J. Danen, Elisa Giovannetti, Thomas Schmidt. Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel. Cancers 2024; 16(22): 3863 doi: 10.3390/cancers16223863
|
| 14 |
Mirco Masi, Laura Poppi, Viola Previtali, Shannon R. Nelson, Kieran Wynne, Giulia Varignani, Federico Falchi, Marina Veronesi, Ennio Albanesi, Daniele Tedesco, Francesca De Franco, Andrea Ciamarone, Samuel H. Myers, Jose Antonio Ortega, Greta Bagnolini, Giovanni Ferrandi, Fulvia Farabegoli, Nicola Tirelli, Giuseppina Di Stefano, Giorgio Oliviero, Naomi Walsh, Marinella Roberti, Stefania Girotto, Andrea Cavalli. Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. Cell Death Discovery 2025; 11(1) doi: 10.1038/s41420-025-02382-3
|
| 15 |
Aarfa Queen, Humaira Naaz Bhutto, Mohd Yousuf, Mansoor Ali Syed, Md. Imtaiyaz Hassan. Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation. Seminars in Cancer Biology 2022; 86: 899 doi: 10.1016/j.semcancer.2022.01.001
|
| 16 |
Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiufeng Zhang, Shengyu Yang, Chongbiao Huang, Jihui Hao, Jing Liu. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Journal of Experimental & Clinical Cancer Research 2023; 42(1) doi: 10.1186/s13046-023-02671-8
|
| 17 |
Jinsheng Ding, Yongjie Xie, Ziyun Liu, Zhaoyu Zhang, Bo Ni, Jingrui Yan, Tianxing Zhou, Jihui Hao. Hypoxic and Acidic Tumor Microenvironment–Driven AVL9 Promotes Chemoresistance of Pancreatic Ductal Adenocarcinoma via the AVL9-IκBα-SKP1 Complex. Gastroenterology 2025; 168(3): 539 doi: 10.1053/j.gastro.2024.10.042
|
| 18 |
Hitoshi Masuo, Koji Kubota, Akira Shimizu, Tsuyoshi Notake, Satoru Miyazaki, Takahiro Yoshizawa, Hiroki Sakai, Hikaru Hayashi, Yuji Soejima. Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines. Cancer Science 2023; 114(11): 4388 doi: 10.1111/cas.15962
|
| 19 |
Kaidong Liu, Yiding Geng, Linzhu Wang, Huanhuan Xu, Min Zou, Yawei Li, Zhangxiang Zhao, Tingting Chen, Fengyan Xu, Liang Sun, Shuliang Wu, Yunyan Gu. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology 2022; 16(16): 3034 doi: 10.1002/1878-0261.13279
|
| 20 |
Sunisa Prasopporn, Orawan Suppramote, Ben Ponvilawan, Chanette Jamyuang, Jantappapa Chanthercrob, Amphun Chaiboonchoe, Pimkanya More-Krong, Kamonchanok Kongsri, Monthira Suntiparpluacha, Rawisak Chanwat, Krittiya Korphaisarn, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1021632
|
| 21 |
Ning Xia, Nannan Yang, Qungang Shan, Ziyin Wang, Xiaoyu Liu, Yingjie Chen, Jian Lu, Wei Huang, Zhongmin Wang. HNRNPC regulates RhoA to induce DNA damage repair and cancer‐associated fibroblast activation causing radiation resistance in pancreatic cancer. Journal of Cellular and Molecular Medicine 2022; 26(8): 2322 doi: 10.1111/jcmm.17254
|
| 22 |
Sheng‐Yi Chen, Yi‐Hao Hsu, Sheng‐Yang Wang, Ying‐Yin Chen, Cheng‐Jie Hong, Gow‐Chin Yen. Lucidone inhibits autophagy and MDR1 via HMGB1/RAGE/PI3K/Akt signaling pathway in pancreatic cancer cells. Phytotherapy Research 2022; 36(4): 1664 doi: 10.1002/ptr.7385
|
| 23 |
Ryan Sasse. A hypothetical dual pH-sensitive nanoparticle strategy for enhanced drug delivery in pancreatic ductal adenocarcinoma. Medical Hypotheses 2025; 198: 111634 doi: 10.1016/j.mehy.2025.111634
|
| 24 |
Sohum Patel, Eleanor Jenkins, Rutuj P Kusurkar, Sherry Lee, Wei Jiang, Avinoam Nevler, Matthew McCoy, Michael J Pishvaian, Rosalie C Sears, Jonathan R Brody, Charles J Yeo, Aditi Jain. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Neoplasia 2025; 63: 101152 doi: 10.1016/j.neo.2025.101152
|
| 25 |
Wei Hu, Mingxu Li, Yan Wang, Chengcheng Zhong, Xinxin Si, Xiao Shi, Zhong Wang. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Aging 2023; 15(1): 92 doi: 10.18632/aging.204455
|
| 26 |
Shwetapadma Dash, Sonali Sahoo, Sanjeeb Kumar Sahoo. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. 2024; : 37 doi: 10.1016/B978-0-443-19142-8.00017-6
|
| 27 |
Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, K. Pavithran, Ashok R. Unni, MS Sithara, Manjit Sarma, T S Mangalanandan. Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics 2024; 21(12): 5960 doi: 10.1021/acs.molpharmaceut.4c00801
|
| 28 |
Yunguang Li, Shijie Tang, Xiaohan Shi, Jingwen Lv, Xueyuan Wu, Yehan Zhang, Huan Wang, Juan He, Yiqin Zhu, Yi Ju, Yajuan Zhang, Shiwei Guo, Weiwei Yang, Huiyong Yin, Luonan Chen, Dong Gao, Gang Jin. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Reports Medicine 2023; 4(9): 101162 doi: 10.1016/j.xcrm.2023.101162
|
| 29 |
Sae Hamaya, Kyoko Oura, Asahiro Morishita, Tsutomu Masaki. Cisplatin in Liver Cancer Therapy. International Journal of Molecular Sciences 2023; 24(13): 10858 doi: 10.3390/ijms241310858
|
| 30 |
Kohei Yamakawa, Michiyo Koyanagi-Aoi, Akihito Machinaga, Nobuyuki Kakiuchi, Tomonori Hirano, Yuzo Kodama, Takashi Aoi. Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. Cancer Cell International 2023; 23(1) doi: 10.1186/s12935-023-02928-4
|
| 31 |
Moises O. Guardado Rivas, Shawn D. Stuart, Daniel Thach, Michael Dahan, Robert Shorr, Zuzana Zachar, Paul M. Bingham, Debabrata Banerjee. Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613. PLOS ONE 2022; 17(6): e0269620 doi: 10.1371/journal.pone.0269620
|
| 32 |
Ingrid Garajová, Marianna Peroni, Fabio Gelsomino, Francesco Leonardi. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. Current Oncology 2023; 30(11): 9587 doi: 10.3390/curroncol30110694
|